Mass. Movers

Aegerion wins approval for its first drug

Aegerion can begin marketing its first drug.

Aegerion can begin marketing its first drug.

The Food and Drug Administration has approved Aegerion Pharmaceuticals’ request to market its first drug, a treatment for a rare inherited genetic disorder that can raise cholesterol to life-threatening levels. The condition is resistant to statins and other medications typically used to bring high cholesterol under control. The Cambridge biotech’s drug, Juxtapid, does carry a risk of liver toxicity, so it will come with a “black box” label — the FDA’s most serious warning level.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.